MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Proceeds from warrantinducements, net of issuance...$51,042K Proceeds from issuance ofcommon stock, common...$23,051K Proceeds from theexercise of common stock...$12,618K Proceeds from employeestock plan purchases$112K Net cash provided byfinancing activities$86,296K Canceled cashflow$527K Net increase incash, cash...$57,907K Canceled cashflow$28,389K Tax withholding onvesting of restricted...$527K Non-cash stock-basedcompensation$1,956K Non-cash lease expense$597K Net cash used inoperating activities-$28,389K Canceled cashflow$2,553K Net loss-$26,863K Accrued expenses andother current...-$1,941K Prepaid expenses andother assets$968K Operating leaseliabilities-$635K Accounts payable-$535K
Cash Flow
source: myfinsight.com

SELLAS Life Sciences Group, Inc. (SLS)

SELLAS Life Sciences Group, Inc. (SLS)